Max Nobis

Dr. Max Nobis

Garvan Institute of Medical Research, Faculty of Medicine, St Vincent’s Clinical School, University of New South Wales (UNSW) Sydney, Darlinghurst, NSW 2010, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CVClaire Vennin
Claire Vennin
VCVenessa T. Chin
Venessa T. Chin
SWSean Warren
Sean Warren
MLMorghan C. Lucas
Morghan C. Lucas
DHDavid Herrmann
David Herrmann
PTPaul Timpson
Paul Timpson
Fine-tuned manipulation of tumor tension and vasculature enhances response to chemotherapy and impairs metastatic spread in pancreatic cancer.

12 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CVClaire Vennin
Claire Vennin
PMPauline Mélénec
Pauline Mélénec
RRRomain Rouet
Romain Rouet
Max NobisMax Nobis
Max Nobis
ACAurélie S. Cazet
Aurélie S. Cazet
PTPaul Timpson
Paul Timpson
Heterogeneous subtypes of cancer-associated fibroblasts (CAFs) coexist within pancreatic cancer tissues and can both promote and restrain disease progression. Here, we interrogate how cancer cells harboring distinct alterations in p53 manipulate CAFs. We reveal the existence of a p53-driven hierarchy, where cancer cells with a gain-of-function (GOF) mutant p53 educate a dominant population of CAFs that establish a pro-metastatic environment for GOF and null p53 cancer cells alike. We also demonstrate that CAFs educated by null p53 cancer cells may be reprogrammed by either GOF mutant p53 cells or their CAFs. We identify perlecan as a key component of this pro-metastatic environment. Using intravital imaging, we observe that these dominant CAFs delay cancer cell response to chemotherapy. Lastly, we reveal that depleting perlecan in the stroma combined with chemotherapy prolongs mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic cancer.

6 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMichael Papanicolaou
Michael Papanicolaou
APAmelia L. Parker
Amelia L. Parker
MYMichelle Yam
Michelle Yam
EFElysse C. Filipe
Elysse C. Filipe
SWSunny Z. Wu
Sunny Z. Wu
TCThomas R. Cox
Thomas R. Cox
The tumour stroma, and in particular the extracellular matrix (ECM), is a salient feature of solid tumours that plays a crucial role in shaping their progression. Many desmoplastic tumours including breast cancer involve the significant accumulation of type I collagen. However, recently it has become clear that the precise distribution and organisation of matrix molecules such as collagen I is equally as important in the tumour as their abundance. Cancer-associated fibroblasts (CAFs) coexist within breast cancer tissues and play both pro- and anti-tumourigenic roles through remodelling the ECM. Here, using temporal proteomic profiling of decellularized tumours, we interrogate the evolving matrisome during breast cancer progression. We identify 4 key matrisomal clusters, and pinpoint collagen type XII as a critical component that regulates collagen type I organisation. Through combining our proteomics with single-cell transcriptomics, and genetic manipulation models, we show how CAF-secreted collagen XII alters collagen I organisation to create a pro-invasive microenvironment supporting metastatic dissemination. Finally, we show in patient cohorts that collagen XII may represent an indicator of breast cancer patients at high risk of metastatic relapse.

1 April 2015 in Cancer Cell
Verified
Journal Article
Closed access
SKSilvia von Karstedt
Silvia von Karstedt
ACAnnalisa Conti
Annalisa Conti
Max NobisMax Nobis
Max Nobis
AMAntonella Montinaro
Antonella Montinaro
THTorsten Hartwig
Torsten Hartwig
HWHenning Walczak
Henning Walczak

1 June 2013 in Molecular Cell
Verified
Journal Article
Open access
ATAntonio Garcia Trinidad
Antonio Garcia Trinidad
Patricia A. J. MullerPatricia A. J. Muller
Patricia A. J. Muller
JCJorge Cuéllar
Jorge Cuéllar
MKMarta Klejnot
Marta Klejnot
Max NobisMax Nobis
Max Nobis
KVKaren H. Vousden
Karen H. Vousden
P53 is a transcription factor that mediates tumor suppressor responses. Correct folding of the p53 protein is essential for these activities, and point mutations that induce conformational instability of p53 are frequently found in cancers. These mutant p53s not only lose wild-type activity but can also acquire the ability to promote invasion and metastasis. We show that folding of wild-type p53 is promoted by an interaction with the chaperonin CCT. Depletion of this chaperone in cells results in the accumulation of misfolded p53, leading to a reduction in p53-dependent gene expression. Intriguingly, p53 proteins mutated to prevent the interaction with CCT show conformational instability and acquire an ability to promote invasion and random motility that is similar to the activity of tumor-derived p53 mutants. Our data therefore suggest that both growth suppression and cell invasion may be differentially regulated functions of wild-type p53.

1 August 2016 in Biomaterials
Verified
Journal Article
Closed access
DKDaniela Kalafatovic
Daniela Kalafatovic
Max NobisMax Nobis
Max Nobis
JSJiye Son
Jiye Son
KAKurt I. Anderson
Kurt I. Anderson
RURein V. Ulijn
Rein V. Ulijn